[DEFINITIONS] Pharma Value Realization & Customer Excellence FAQs

Introduction

Pharma commercial leadership has a vocabulary problem, and it is costing money.

The industry has precise, shared language for everything upstream of the prescription: reach, frequency, share of voice, NBRx, TRx, segmentation, targeting, next-best-action. It has almost no shared language for what happens after. When a written script does not become initiated therapy, or when initiated therapy does not become sustained therapy, the loss is real, financially material, and largely unnamed. What cannot be named cannot be budgeted against, measured, or owned.

This FAQ defines the terms. It is written for Chief Commercial Officers, VPs of Commercial Excellence, Brand and Franchise Leads, Heads of Field Operations, and Patient Services leaders who suspect their commercial system is leaking value between intent and impact but lack the framework to quantify it or the operating model to close it.

By the end, the reader will have working definitions for Customer Excellence, Customer Value at Risk, Journey Operations, and the three paths across which pharma value is created and lost — plus a clear view of which of these are strategy problems, which are system problems, and which are culture problems wearing a technology costume.

Market Context: The Value Leakage Economy

Pharma's commercial investment is heavily front-loaded. The overwhelming majority of commercial spend is deployed to create prescribing intent — medical education, field deployment, digital engagement, brand building, launch orchestration. That investment works. Pharma is extraordinarily good at earning the script.

The structural problem begins the moment the script is earned. Across two decades inside global pharma commercial organizations — Pfizer's Chief Marketing Office and Bayer's Customer Powerhouse — I watched brands in some therapeutic areas lose as much as half of their written prescriptions before those scripts ever became initiated therapy. That figure is not drawn from published research. It is what I observed from inside the system, repeatedly, across therapeutic areas and markets.

Patients abandon at the pharmacy counter over cost. Prior authorization stalls. Specialty pharmacy handoffs drop context. Patient support enrollment never completes. Titration confusion produces early discontinuation. Each of these is a separate functional responsibility, tracked by a separate team, against a separate definition of success.

No one owns the sum. And here is the more revealing part: in most of the organizations I have worked with since, no one could tell me what their own number was. The inability to answer is the finding. A commercial organization that cannot state what percentage of its written scripts become initiated therapy is not managing a known loss. It is carrying an unmeasured one.

That is the shift worth naming: the competitive frontier in pharma commercial has moved from demand creation to demand realization. Two organizations can generate identical prescribing intent and produce materially different revenue, because one has an experiential system that carries intent through to therapy and the other does not. The organizations that build that system first will not simply perform better — they will be difficult to catch, because experiential capability compounds and cannot be purchased in a budget cycle.

This is not a marketing observation. It is a P&L observation. Every point of value leakage is revenue already paid for and not collected.

The Questions

The questions below are the ones commercial leaders raise most often when they first encounter the value realization frame — and the ones they raise later, when they try to operationalize it.

a. Definitions

What is Customer Excellence in pharma, and how is it different from Commercial Excellence?

Customer Excellence is the discipline of designing and operating the commercial system so that clinical intent reliably becomes realized therapeutic and commercial value. Commercial Excellence, as practiced in most pharma organizations, optimizes the machinery of demand creation: targeting accuracy, call quality, channel mix, launch sequencing, resource allocation. Customer Excellence does not replace it. It integrates Marketing Excellence, Sales Excellence, and Launch Excellence into a single operating system and extends that system across the full journey — including the portion after the prescribing decision, where most organizations have no unified ownership at all.

The practical difference is where each discipline looks for growth. Commercial Excellence asks how to generate more intent from the same investment. Customer Excellence asks how much intent the organization is already generating and failing to convert. In stalled brands with strong prescribing data, the second question is usually the more productive one.

What is the value realization gap?

The value realization gap — also described as the intent-to-impact gap — is the measurable distance between the clinical intent a commercial organization successfully creates and the therapeutic and commercial value it ultimately realizes.

It is visible in a specific pattern: prescribing metrics look healthy, promotional response holds, HCP sentiment is stable, and revenue underperforms anyway. Because the leakage occurs across functional boundaries — field to access, access to specialty pharmacy, pharmacy to patient services, patient services to adherence — no single dashboard displays it. Each function reports performance within its own scope and each report is accurate. The gap lives in the handoffs, which is precisely where no function is accountable.

The gap is not evidence of a weak brand or a weak field organization. It is evidence of a commercial system designed around promotional behaviors and never redesigned around journey progression.

What is Customer Value at Risk (CVaR)?

Customer Value at Risk is the quantified commercial exposure created by friction, fragmentation, and failed handoffs across the customer and patient journey. It is the compounding drag that sits between intent and impact.

CVaR borrows deliberately from financial risk language, because that is the register in which it should be managed. Organizations do not treat credit risk or supply risk as a soft issue to be addressed when convenient; they quantify it, assign ownership, and manage it down. Journey friction deserves the same treatment. Every unresolved barrier — a prior authorization loop, an unenrolled patient, an unanswered titration question, a lost specialty pharmacy handoff — carries a probability-weighted revenue value that can be estimated, tracked, and reduced.

CVaR appears in the Value Realization formula as a discount on everything else the organization creates:

Value Realization = (Brand × Product × Experience)^Culture × (1 − CVaR)

Brand creates belief. Product creates clinical possibility. Experience progresses intent into impact. Culture determines whether progression repeats or stays episodic. CVaR determines how much of the resulting value the organization actually keeps. The formula performs when Culture amplifies the multiplier and CVaR approaches zero.

Why is "Consumer-Grade" the benchmark, and why now?

Because HCPs and patients no longer calibrate their expectations against other pharmaceutical companies. They calibrate against every other experience in their lives.

The physician navigating a fragmented prior authorization process on Tuesday afternoon booked a flight, resolved a banking dispute, and reordered a prescription for her own household that same week — each in minutes, each with continuity, each without repeating herself. Her tolerance for administrative burden is set by those experiences, not by pharma's internal benchmarks. Consumer-Grade is not an aesthetic standard. It is a burden standard.

This matters commercially because burden influences prescribing behavior. When initiating a therapy is operationally harder than initiating a competitor's, that difficulty enters the clinical decision even when the clinical evidence favors the harder option. Experience has become a variable in the prescribing equation, which means it has become a variable in the revenue equation.

b. How the system works

What is Journey Operations, and how is it different from omnichannel?

Omnichannel is a distribution discipline. It governs which message reaches which customer through which channel at which moment, and it is largely oriented toward the promotional phase of the journey.

Journey Operations is a progression discipline. It governs whether a customer or patient advances from one journey state to the next — from intent to initiation, from initiation to persistence — and it treats stalls as operational defects with owners, root causes, and resolution paths. Omnichannel asks whether the message was delivered. Journey Operations asks whether the patient started therapy.

The distinction is not academic. An organization can achieve excellent omnichannel maturity — orchestrated, personalized, well-measured — while the value realization gap widens, because more coordinated messaging does nothing about a broken specialty pharmacy handoff. Channel orchestration and journey progression are different capabilities. Most organizations have invested heavily in the first and structurally in neither.

What is FieldOS, and why does field intelligence matter more in an AI era, not less?

FieldOS is a reference architecture for embedding Journey Operations into field enablement — turning the field organization from a message delivery channel into a barrier-detection and barrier-removal engine.

The prevailing industry narrative holds that the field is expensive, hard to scale, and increasingly a supporting actor to data and AI. That narrative misreads what the field actually produces. Field organizations conduct millions of nuanced clinical conversations annually inside the real complexity of a physician's practice — formulary friction, patient mix, clinical hesitation, competitive counter-messaging, accumulated brand history. That intelligence exists nowhere else in the commercial system. No digital signal captures it. No dashboard contains it. In most organizations, it evaporates the moment the call ends.

The contrarian position is straightforward: AI's highest value in a field context is not to replace what the field does but to amplify it. Structured capture of frontline barrier intelligence, synthesized at scale and routed to the functions that can resolve it, is a capability competitors cannot license. Technology platforms can be purchased. Earned clinical trust, and the operating discipline to act on what it reveals, cannot.

Where does value actually leak — Path-to-Prescribe, Path-to-Fulfill, or Path-to-Adhere?

The three paths describe the full arc across which pharmaceutical value is created and lost.

Path-to-Prescribe is where evidence, education, and clinical confidence shape the prescribing decision. This is where pharma invests most and performs best.

Path-to-Fulfill is where the script becomes therapy in the patient's hands — access, affordability, prior authorization, specialty pharmacy coordination, patient readiness. This is where the largest and least visible leakage occurs, because it spans functions that report to different leaders and is measured by process metrics rather than progression outcomes.

Path-to-Adhere is where therapy becomes outcome — onboarding, titration support, side-effect management, refill continuity, sustained belief. Leakage here is slower, quieter, and compounds over the life of the brand.

In practice, most organizations discover their concentration of CVaR in Fulfill and their most expensive long-run leakage in Adhere. Both sit outside the traditional commercial scope, which is exactly why they persist.

c. Building the capability

How do you quantify value leakage? What should be measured?

The measurement principle is that only progression metrics count. Activity metrics — reach, frequency, impressions, calls, enrollments initiated — describe effort. Progression metrics describe whether the customer or patient moved.

The core set:

• Script-to-start conversion — the percentage of written prescriptions that become initiated therapy, segmented by payer, channel, geography, and HCP cohort. This single metric surfaces most Fulfill-stage leakage.
• Time-to-therapy — elapsed days from prescribing decision to first dose. Duration is a proxy for accumulated friction; it is often more diagnostic than the conversion rate itself.
• Stall points by journey state — where progression halts, at what volume, with what recoverable revenue attached. This is the raw material of CVaR.
• Persistence at defined intervals — 30, 90, 180 days, cohort-compared against patients who did and did not encounter a specific barrier.
• Barrier resolution rate and cycle time — the operational health measure of Journey Operations. Detection without resolution is reporting, not capability.
• Realized value per unit of demand created — the executive-level ratio, and the one that connects this discipline to the P&L.

The discipline test is whether a commercial leader can state, in dollars, what a specific journey barrier costs the brand annually. If not, the organization is describing friction rather than managing it.

What technology is required — and is technology the constraint?

Technology is rarely the binding constraint, and treating it as one is the most common and most expensive diagnostic error in this space.

Most large pharma organizations already own the necessary components: CRM, MCM and orchestration platforms, patient services systems, specialty pharmacy data feeds, claims and dispensing data, and increasingly a CDP or unified data layer. The barrier is not capability absence. It is that these systems were architected around functional accountability rather than journey progression, so the data required to see a single patient's or physician's path exists but is never assembled into one view.

What must be added is usually architectural and organizational rather than technological: a shared definition of journey states, a single owner for progression across functional boundaries, an instrumented barrier-capture mechanism at the field and service edge, and a governance forum with the authority to resolve issues that cross functions. Organizations that begin by procuring a platform typically discover eighteen months later that they have automated an unresolved ownership problem.

Why do digital, omnichannel, and AI transformations fail to close this gap?

Because transformation modernizes tools without challenging the mental models that define success.

A transformation program that improves targeting precision, expands channel coverage, and accelerates content production makes the organization more efficient at executing its existing pattern. If that pattern is oriented toward demand creation, the result is more efficient demand creation — and an unchanged, or wider, realization gap. Efficiency applied to the wrong half of the system produces sophistication without impact.

There is a second failure mechanism that is less discussed. Channel proliferation increases the cognitive burden on the HCP. Adding touchpoints while leaving underlying friction intact makes the brand harder to engage with, not easier. Several organizations have improved every engagement metric on their dashboard while their actual burden profile deteriorated.

The question that separates programs that work from programs that do not is simple and rarely asked: did this investment reduce the effort required of the physician or the patient, or did it multiply the number of things they must navigate?

How long does it take to build a value realization capability?

Sequencing determines outcome more than duration does.

A focused diagnostic — instrumenting one brand in one market to quantify script-to-start conversion, identify concentrated stall points, and size CVaR against the P&L — is typically a matter of weeks, not quarters, because most of the required data already exists inside the organization. This phase produces the number that makes the case.

Standing up Journey Operations for a priority brand — defined journey states, assigned progression ownership, field barrier capture in the workflow, a functioning cross-functional resolution forum — generally runs one to two quarters, and is where most of the recoverable value is first realized.

Making the capability structural across a portfolio and multiple markets — embedded in planning cycles, incentive design, launch playbooks, and leadership standards — is a multi-year cultural build. That is the exponent in the formula, and it is the part that cannot be compressed.

Organizations that attempt the enterprise build before proving the brand-level number consistently stall, because they are asking for structural change without evidence attached.

Does this work in a regulated environment, and does it scale across markets?

Regulatory constraint is frequently offered as the reason pharma cannot deliver Consumer-Grade experiences. It is rarely the actual reason.

MLR governs claims, promotional content, and communication about products. It does not govern how quickly a prior authorization is resolved, whether a patient services handoff preserves context, whether a physician has to supply the same information three times, or whether an organization notices that a patient never started therapy. The overwhelming majority of journey friction is operational rather than promotional, and therefore fully addressable within existing regulatory constraint. Organizations that have made real progress here typically found that compliance was a design input, not a ceiling.

International scaling introduces genuine variation: access architecture, payer structure, patient support models, data residency, and channel norms differ materially by market. The scaling pattern that works is a consistent global architecture — shared journey state definitions, common CVaR methodology, comparable progression metrics — with local ownership of barrier resolution, because the barriers themselves are market-specific. Standardize the diagnostic. Localize the remedy.

What Closing the Gap Delivers

The returns from value realization work differ from promotional returns in an important way: they are recovery rather than acquisition. The demand has already been paid for. Closing the gap collects revenue the organization has already earned and is currently forfeiting.

In practice, this has produced measurable movement in three places:

Brand trajectory recovery. A stalled high-priority launch restored to a 12% NBRx growth turnaround — achieved without added promotional intensity, by removing progression barriers rather than generating more intent.

Field organization leverage. A field-led revenue uplift exceeding 30%, generated by operationalizing frontline and HCP experiential intelligence into enterprise ways of working rather than expanding headcount or call volume.

Signal-driven commercial improvement at scale. Voice-of-customer signals rewired into commercial decision-making across 100+ markets, spanning digital, field, and DTC channels.

The pattern is consistent. The largest available gains in mature commercial organizations are not in creating additional demand. They are in stopping the loss of demand already created.

d. Deep-Dive Sections

Why the Gap Is Structural, Not Behavioral

The most common misdiagnosis of the value realization gap is that it is an execution or effort problem — that field teams need better training, that patient services needs more staff, that access needs stronger messaging. Each of those may be true and none of them addresses the cause.

The gap is structural because the commercial system was designed to optimize a phase, not a journey. Every function in the post-prescription chain is doing its job well, measured against a definition of success it did not choose and cannot see beyond. Field is measured on reach and quality of engagement. Access is measured on formulary position. Patient services is measured on enrollment volume. Specialty pharmacy is measured on fill rate. All four can hit target while script-to-start conversion declines, because no one is measured on the thing that connects them.

This is why exhortation fails and why reorganization alone fails. The remedy is a progression layer that runs horizontally across functions, with its own definition of success, its own instrumentation, and enough authority to resolve issues that no single function owns. That is what Journey Operations is for.

How Culture Functions as the Exponent

In the Value Realization formula, Culture is not a multiplier. It is an exponent — a deliberate structural claim rather than a rhetorical flourish.

Multipliers scale linearly. Exponents determine whether a system compounds or decays. A commercial organization can execute a well-designed journey intervention on a priority brand and generate real recovery, then watch that recovery dissipate as attention moves to the next launch. The intervention worked. The organism did not change. That is episodic progression, and it is what most transformation programs actually purchase.

Culture, in this specific sense, is not values or engagement scores. It is what the organization does by default when no one is watching: whether a field professional captures a barrier because the system makes it natural, whether a cross-functional stall gets escalated without a mandate, whether leaders ask about progression in a brand review unprompted. When those defaults hold, every subsequent intervention compounds on the last. When they do not, each initiative starts from zero and the same barriers reappear under new names.

When to Instrument Versus When to Intervene

There is a practical sequencing decision most organizations get backwards.

Instrumentation — establishing journey states, measuring script-to-start conversion, sizing CVaR — should almost always precede intervention. Not because measurement is intrinsically virtuous, but because journey barriers concentrate. In most brands, a small number of stall points account for a disproportionate share of leaked value, and they are frequently not the ones leadership assumed. Organizations that intervene first typically fix the visible barrier rather than the expensive one.

The exception is worth naming. When a barrier is already known, already quantified, and already owned, further diagnostic work is avoidance dressed as rigor. Sizing an obvious problem for another two quarters is a way of not fixing it.

The judgment: instrument when the leakage is diffuse or contested; intervene when it is concentrated and agreed. Most organizations need the first and reach for a platform instead.

Common Misconceptions

"This is a patient services issue." Patient services owns a segment of the journey, not the journey. Locating value realization inside patient services guarantees that field-stage and access-stage leakage remains unaddressed, and it caps the discipline's authority below the level required to resolve cross-functional stalls.

"Experience is soft and cannot be tied to revenue." Experience that cannot be tied to patient outcomes and realized commercial value will always lose the budget argument — correctly. The discipline is only credible when it produces a dollar figure. That is the entire purpose of CVaR: to move experience from the language of sentiment into the language of exposure.

"We already do this — it is our omnichannel program." Channel orchestration and journey progression are different capabilities with different owners, different metrics, and different failure modes. The diagnostic question: can the organization report script-to-start conversion by barrier type? If not, it has an omnichannel program.

"Regulation prevents Consumer-Grade experience." Regulation governs claims. It does not govern burden. The distinction is where the addressable opportunity lives.

"AI will close this." AI applied to demand creation widens the gap by increasing intent the system still cannot convert. AI applied to barrier detection and journey progression closes it. The technology is identical; the orientation determines the outcome.

How The Customer Excellence Agency Can Help

The Customer Excellence Agency works with pharmaceutical and life sciences commercial leaders to close the value realization gap structurally, systemically, and consistently.

The work follows the formula. Accelerate Brand Growth identifies where demand is failing to become patient progression, quantifies the leakage, removes the barriers, and recovers the growth. Strengthen Field Performance positions the field organization as a barrier-detection and removal engine, converting frontline intelligence into activation through the FieldOS architecture. Scale Customer Excellence embeds value realization mechanisms into how the commercial organization thinks, decides, and operates — making the capability structural rather than episodic.

The methodology was not assembled from the outside. It was built inside global pharma — through Pfizer's Chief Marketing Office and Bayer's Customer Powerhouse — on a foundation of experience discipline drawn from Ritz-Carlton, LG, and Mastercard, then codified with a founding faculty colleague of Michigan State University's Customer Experience Management master's program and published by Wiley as The Customer Excellence Enterprise, now adopted in graduate and enterprise capability programs.

Conclusion & Next Steps

Pharma does not have a demand problem. It has a value leakage problem, and the leakage is invisible precisely because every function reporting on it is reporting accurately.

The most useful next step for most commercial organizations is narrow rather than broad: take one priority brand in one significant market and establish a single number — what percentage of written scripts become initiated therapy, and what the shortfall is worth annually. That number does more to mobilize an organization than any framework, because it converts an abstract concern into recognized exposure. Everything else — the operating model, the field architecture, the governance, the cultural build — becomes tractable once the exposure is named.

Breakthrough science that never reaches the patient might as well not exist. Together, we can make sure more of it does.

[Schedule a Diagnostic Conversation →]